drugset / Trial / NCT03778541
HFSRT With Concurrent TMZ for Large BMs
RandomizedParallel-groupOpen-labelTreatment
Summary
A multi-center randomized phase III trial was conducted to investigate the feasibility and safety of adding temozolomide to hypofractionated stereotactic radiotherapy for large brain metastases.
Timeline
- Start
- 2018-12-03
- Primary completion
- 2022-12-03
- Completion
- 2022-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | 75 mg/m2 | — |